Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Being Overweight Is A Health Concern, BMI Is Only Part Of The Story
Being overweight is a health concern, but Body Mass Index doesn"t tell the whole story because it is part of a larger picture, says a new advisory
generic viagra online
Characterization Of ERG, AR And PTEN Gene Status In Circulating Tumor Cells From Patients With Castration-Resistant Prostate Cancer
UroToday.com - The TMPRSS2-ERG gene fusion occurs in 30-70% of androgen deprivation therapy (ADT) naç¯ve prostate cancers (CaP), but its relevance in castration-resistant prostate cancer (CRPC) is less well defined. The TMPRSS2-ERG gene fusion is androgen driven. In the April 1, 2009 issue of Cancer Research, a group led by Dr. Johann de Bono evaluated patients undergoing treatment with the CYP17 inhibitor abiraterone acetate, which ablates the synthesis of androgens and estrogens that drive the TMPRSS2-ERG gene fusions. They hypothesized that androgen-dependent overexpression of ERG persisted in CRPC and that TMPRSS2-ERG tumors represented a subgroup of CaP that remained sensitive to abiraterone acetate. They hypothesized that two mechanisms of resistance to abiraterone acetate were gain of AR and loss of PTEN that could result in constitutive phosphorylation of AR, leading to ligand-independent activation.
News of the day
Study Shows Even Moderately Elevated Cholesterol Level Boosts Dementia Risk
Elevated cholesterol levels in midlife - even levels considered only borderline elevated - significantly increase the risk of Alzheimer"s disease and vascular dementia later in life, according to a new study by researchers at Kaiser Permanente"s Division of Research and the University of Kuopio in Finland. The study appears in the journal Dementia & Geriatric Cognitive Disorders.
Endocrinology

Centocor Ortho Biotech Statement On The FDA ODAC Opinion Regarding Trabectedin For Relapsed Ovarian Cancer

Based on the data presented, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended that the combination of trabectedin when administered with DOXIL(R) (doxorubicin HCI liposome injection) did not provide a sufficient benefit-risk profile for the treatment of relapsed ovarian cancer. Ovarian cancer is difficult to treat and the disease often recurs in patients who previously have been treated with platinum-based therapy, underscoring the need for non-platinum treatment options. Centocor Ortho Biotech Products continues to believe trabectedin has an important role in the treatment of recurrent ovarian cancer. The company remains committed to working with the FDA to address the committee"s concerns. The committee provides non-binding recommendations based on its evaluation. The final decision regarding approval of the drug will be made by the FDA. About Trabectedin Trabectedin is a novel cytotoxic antitumor agent that was originally derived from the marine tunicate, Ecteinascidia turbinata. The compound is now produced synthetically. Trabectedin binds to the minor groove of DNA and bends it toward the major groove, causing DNA adducts that interfere with cell division and genetic transcription processes and DNA repair machinery. Under a licensing agreement with PharmaMar SAU of Spain, Centocor Ortho Biotech Products, L.P. has worldwide marketing rights for trabectedin except in Europe and Japan, where the product is marketed as YONDELIS(R) by PharmaMar SAU. About Centocor Ortho Biotech Products, L.P. Centocor Ortho Biotech redefines the standard of care in immunology, nephrology, and oncology. The company was formed when Centocor, Inc. and Ortho Biotech Products, L.P. were consolidated in late 2008, and was renamed Centocor Ortho Biotech. Built upon a pioneering history, Centocor Ortho Biotech harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates, and healthcare professionals have access to the latest treatment information, support services, and quality care. Centocor Ortho Biotech Products, L.P. is a member of the Johnson & Johnson Family of Companies. Centocor Ortho Biotech Products, L.P


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009